Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the ...

The Boston-based biotech said today that the orally-active GPR6 inverse agonist reduced the time people with Parkinson's experienced so-called 'off' episodes, when symptoms of the illness re ...

The endocannabinoid system and its ability to regulate metabolism has held promise for the development of therapeutic agents to combat the growing epidemic of obesity. Two randomized, placebo ...